Handelsbanken Fonder Ab Coherus Bio Sciences, Inc. Transaction History

Handelsbanken Fonder Ab

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 07, 2023	BUY	$5.69 - $10.07 $40,968 - $72,504	7,200 Added 38.3%	26,000 $206,000
Q2 2021 Aug 03, 2021	BUY	$12.95 - $15.41 $111,370 - $132,526	8,600 Added 84.31%	18,800 $260,000
Q2 2020 Aug 13, 2020	BUY	$14.43 - $19.16 $147,186 - $195,432	10,200 New	10,200 $182,000
Q4 2017 Feb 08, 2018	SELL	$8.35 - $14.4 $584,500 - $1.01 Million	-70,000 Closed	0 $0
Q3 2017 Oct 24, 2017	BUY	$11.1 - $14.5 $777,000 - $1.02 Million	70,000	70,000 $934,000

130

67.8M

1.68M

91.8K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $71.5M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

Stay updated on Handelsbanken Fonder Ab with notifications on news.